← Back to Screener
Enlivex Ltd. Ordinary Shares (ENLV)
Price$0.71
Value ScoreA
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-34.73%
Price vs S&P 500 (4W)-7.78%
VGM Score60.67
Market Capitalization$171.14M
P/E Ratio (Annual)0.14x
All Metrics
Book Value / Share (Quarterly)$8.15
P/TBV (Annual)0.60x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.04
Price vs S&P 500 (YTD)-7.16%
EPS (TTM)$9.85
10-Day Avg Trading Volume0.66M
EPS Excl Extra (TTM)$9.85
EPS (Annual)$25.48
ROI (Annual)63.85%
Cash / Share (Quarterly)$0.02
P/E Basic Excl Extra (TTM)0.14x
P/E Normalized (Annual)0.14x
ROA (Last FY)53.10%
EBITD / Share (TTM)$-0.30
ROE (5Y Avg)-33.62%
Cash Flow / Share (Annual)$-0.04
P/B Ratio0.09x
P/B Ratio (Quarterly)0.01x
Net Income / Employee (Annual)$36,339,100
Net Interest Coverage (TTM)-4.92x
ROA (TTM)206.39%
EV / EBITDA (TTM)0.49x
EPS Incl Extra (Annual)$25.48
Current Ratio (Annual)193.24x
Quick Ratio (Quarterly)192.76x
3-Month Avg Trading Volume0.51M
52-Week Price Return-22.83%
P/E Incl Extra (TTM)0.14x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.72
52-Week High$2.10
EPS Excl Extra (Annual)$25.48
CapEx CAGR (5Y)-41.82%
Tangible BV CAGR (5Y)78.21%
26-Week Price Return-26.80%
Quick Ratio (Annual)192.76x
13-Week Price Return-36.61%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)193.24x
Enterprise Value$169.25M
Book Value / Share Growth (5Y)27.36%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.02
3-Month Return Std Dev82.47%
Net Income / Employee (TTM)$36,339,100
ROE (Last FY)63.85%
Net Interest Coverage (Annual)-19.36x
EPS Basic Excl Extra (Annual)$25.48
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$9.85
ROI (TTM)248.08%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.09
Price vs S&P 500 (52W)-47.19%
P/E Ratio (TTM)0.14x
Year-to-Date Return1.00%
5-Day Price Return-17.77%
EPS Normalized (Annual)$25.48
ROA (5Y Avg)-28.24%
Month-to-Date Return-12.38%
Cash Flow / Share (TTM)$-1.59
EBITD / Share (Annual)$-0.30
ROI (5Y Avg)-33.62%
P/E Excl Extra (TTM)0.14x
EPS Basic Excl Extra (TTM)$9.85
P/TBV (Quarterly)0.67x
P/B Ratio (Annual)0.01x
Book Value / Share (Annual)$8.15
Price vs S&P 500 (13W)-44.86%
Beta1.50x
Revenue / Share (TTM)$0.00
ROE (TTM)248.08%
52-Week Low$0.66
vGradeA
mGradeD
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ENLVEnlivex Ltd. Ordinary Shares | A | — | D | $0.71 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Enlivex Ltd is a clinical-stage immunotherapy company developing Allocetra, a macrophage reprogramming therapy for osteoarthritis currently in late-stage clinical development. The company's platform leverages immune cell reprogramming technology to address degenerative joint disease.